Knowledge

HKBU and CUHK jointly develop new drug JCM-16021 for the treatment of Irritable Bowel Syndrome

05 Mar 2019

Professor Bian Zhaoxiang (left) and Professor Justin Wu explain the research development process and the effectiveness of JCM-16021

The JCM-16021 contains Rhizoma Atractylodis Macrocephalae (白朮), Radix Paeoniae Lactiflorae (白芍), Cortex Magnoliae Officinalis (/厚樸), Semen coicis Lachryma-jobi (薏苡仁), Polygonaceae (火炭母), Fructus Terminaliae Chebulae (訶子) and Rhizoma Corydalis Yanhusuo (延胡索)

Researchers from Hong Kong Baptist University (HKBU) and the Chinese University of Hong Kong (CUHK) have developed a new formula, called JCM-16021, for the treatment of Irritable bowel syndrome (IBS). The novel drug will be subjected to a large-scale clinical trial with the aim of providing an additional effective therapy option for patients.

For more details, please visit:

https://cpro.hkbu.edu.hk/en/press_release/detail/HKBU-and-CUHK-jointly-develop-new-drug-JCM-16021-for-the-treatment-of-Irritable-Bowel-Syndrome/

Staff achievement, Research/Survey, Chinese Medicine